Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

121. Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants

Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants Gieruszczak-Bialek D, Skorka A, Szajewska H CRD summary The review evaluated the safety and effectiveness of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease in infants (...) and found limited evidence that omeprazole significantly reduced reflux. The review was generally well conducted. The authors’ conclusion that there was insufficient evidence for the use of proton pump inhibitors for treatment of gastro-oesophageal reflux disease in infants seems reliable. Authors' objectives To evaluate the safety and effectiveness of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease (GORD) in infants. Searching MEDLINE (1966-2007), EMBASE (1980-2007

2008 DARE.

122. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). Full Text available with Trip Pro

Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). To determine the cost effectiveness of Helicobacter pylori "test and treat" compared with empirical acid suppression in the initial management of patients with dyspepsia in primary care.Randomised controlled trial.80 general practices in the United Kingdom.699 patients aged 18-65 who presented to their general practitioner (...) with epigastric pain, heartburn, or both without "alarm symptoms" for malignancy.H pylori 13C urea breath test plus one week of eradication treatment if positive or proton pump inhibitor alone; subsequent management at general practitioner's discretion.Cost effectiveness in cost per quality adjusted life year (QALY) (EQ-5D) and effect on dyspeptic symptoms at one year measured with short form Leeds dyspepsia questionnaire.343 patients were randomised to testing for H pylori, and 100 were positive

2008 BMJ Controlled trial quality: uncertain

123. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention

Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention Saini S D, Schoenfeld P, Fendrick A M, Scheiman J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of long-term therapy with low-dose aspirin (ASA) plus proton-pump inhibitor (PPI) co-therapy, compared with ASA alone, for the prevention of upper gastrointestinal bleeding

2008 NHS Economic Evaluation Database.

124. The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis

The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease (...) with the proton-pump inhibitor (PPI) omeprazole and laparoscopic Nissen fundoplication in the management of patients with long-term gastro-oesophageal reflux disease. The authors concluded that PPIs were the cost-effective option when symptom-free months and quality-adjusted life-years were used as benefit measures. In summary, with a few exceptions, the methods were transparent and clearly reported. The authors’ conclusions appear to be appropriate. Type of economic evaluation Cost-effectiveness analysis

2008 NHS Economic Evaluation Database.

125. Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial

Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

126. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial)

Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

127. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding Full Text available with Trip Pro

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could (...) not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Proton pump inhibitor (PPI) treatment may be an effective treatment for peptic ulcer bleeding in those patients with high-risk endoscopic findings. {{author}} {{($index An error has occurred in processing the XML document An error has occurred in processing the XML document

2007 NIHR HTA programme

128. Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery?

Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery? BestBets: Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery? Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery? Report By: Maren Ziegelin, Andreas Hoschtitzky, Joel (...) to aspirin and a proton-pump inhibitor] for the prevention of [gastrointestinal bleeding or complications or peptic ulcers]? Clinical Scenario You are seeing a 72 year old man 8 days post-CABG. He had some melaena on day 2 and endoscopy showed a duodenal ulcer, which was injected. He has had no more symptoms or signs of continued bleeding and you would like to resume anti-platelet therapy. You have heard that clopidogrel is better for your stomach and decide to restart this instead of aspirin, but later

2007 BestBETS

129. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. (Abstract)

Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. BACKGROUND & AIMS: Use of proton pump inhibitors (PPIs) has been associated with elevated levels of serum gastrin. Because hypergastrinemia increases colorectal mucosa proliferation and has been associated with risk of colorectal cancer (CRC) in human beings, we conducted a large population-based study in Denmark to assess whether PPI use is associated with CRC risk. METHODS: We conducted

2007 EvidenceUpdates

130. Review: insufficient evidence exists on the effectiveness of proton pump inhibitors for adults with prolonged non-specific cough associated with gastro-oesophageal reflux

Review: insufficient evidence exists on the effectiveness of proton pump inhibitors for adults with prolonged non-specific cough associated with gastro-oesophageal reflux Review: insufficient evidence exists on the effectiveness of proton pump inhibitors for adults with prolonged non-specific cough associated with gastro-oesophageal reflux | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your (...) of proton pump inhibitors for adults with prolonged non-specific cough associated with gastro-oesophageal reflux Article Text Treatment Review: insufficient evidence exists on the effectiveness of proton pump inhibitors for adults with prolonged non-specific cough associated with gastro-oesophageal reflux Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service

2007 Evidence-Based Nursing

131. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. (Abstract)

Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Guidelines on pain management recommend that patients at risk of ulcers receive either a cyclo-oxygenase (COX 2) inhibitor or a non-steroidal anti-inflammatory drug (NSAID) with a proton-pump inhibitor (PPI). These two treatments have similar effectiveness, but they are insufficient for protection of patients at very (...) high risk for ulcer bleeding. We aimed to test the hypothesis that in patients with previous ulcer bleeding induced by non-selective NSAIDs, combined treatment with the COX 2 inhibitor celecoxib and the PPI esomeprazole would be better than celecoxib alone for prevention of recurrent ulcer bleeding.441 consecutively presenting patients who were taking non-selective NSAIDs for arthritis were recruited to our single-centre, prospective, randomised, double-blind trial after admission to hospital

2007 Lancet Controlled trial quality: predicted high

132. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: PPI therapy in patients with endoscopically documented acute bleeding from a peptic ulcer

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: PPI therapy in patients with endoscopically documented acute bleeding from a peptic ulcer Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: PPI therapy in patients with endoscopically documented acute bleeding from a peptic ulcer Systematic reviews of the clinical (...) effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: PPI therapy in patients with endoscopically documented acute bleeding from a peptic ulcer Leontiadis G I, Sreedharan A, Dorward S, Barton P, Delaney B, Howden C W, Orhewere M, Gisbert J, Sharma V K, Rostom A, Moayyedi P, Forman D CRD summary The authors concluded that proton pump inhibitors reduced re-bleeding; no overall effect was observed on mortality. Overall, this was a well-conducted review

2007 DARE.

133. Meta-analysis: duration of first-line proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication

Meta-analysis: duration of first-line proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication Meta-analysis: duration of first-line proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication Meta-analysis: duration of first-line proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication Fuccio L, Minardi M E, Zagari R M, Grilli D, Magrini N, Bazzoli F CRD summary This well-conducted review concluded that extending proton-pump (...) inhibitor-based triple therapy beyond 7 days for the eradication of Helicobacter pylori is unlikely to be clinically useful. This conclusion is supported by the data presented, but it may not be reliable given the poor methodological quality of the included studies. Authors' objectives To evaluate the efficacy of different durations of proton-pump inhibitor (PPI)-based triple therapy for the eradication of Helicobacter pylori (H. pylori). Searching PubMed, EMBASE and the Cochrane Library were searched

2007 DARE.

134. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: PPI therapy initiated prior to endoscopy

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: PPI therapy initiated prior to endoscopy Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: PPI therapy initiated prior to endoscopy Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal (...) bleeding: PPI therapy initiated prior to endoscopy Leontiadis G I, Sreedharan A, Dorward S, Barton P, Delaney B, Howden C W, Orhewere M, Gisbert J, Sharma V K, Rostom A, Moayyedi P, Forman D CRD summary This review found limited evidence that proton pump inhibitor (PPI) therapy prior to endoscopy for upper gastrointestinal bleeding may reduce the incidence of stigmata of recent haemorrhage, but not other outcomes. Despite some concerns about potential differences between studies and the risk

2007 DARE.

135. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: H. pylori eradication therapy

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: H. pylori eradication therapy Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: H. pylori eradication therapy Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: H. pylori (...) ' conclusions H. pylori eradication therapy reduced rates of bleeding compared to non-eradication antisecretory therapy, including proton pump inhibitors (PPI), with or without subsequent long-term maintenance antisecretory therapy. It was not possible to draw conclusions for the comparison of different types of antisecretory therapies with each other or placebo, particularly in H. pylori negative patients, due to a paucity of evidence. CRD commentary The review question was clear and was supported by clear

2007 DARE.

136. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: H. pylori eradication versus proton pump inhibitors

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: H. pylori eradication versus proton pump inhibitors Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: H. pylori eradication versus proton pump inhibitors Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper (...) gastrointestinal bleeding: H. pylori eradication versus proton pump inhibitors Leontiadis G I, Sreedharan A, Dorward S, Barton P, Delaney B, Howden C W, Orhewere M, Gisbert J, Sharma V K, Rostom A, Moayyedi P, Forman D CRD summary This review found no direct evidence to determine whether long-term aspirin or non-aspirin NSAID use prevented further upper gastrointestinal bleeding. There were no treatment differences between proton pump inhibitor and H. pylori eradication therapy in patients diagnosed with H

2007 DARE.

137. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: Prophylactic PPI therapy

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: Prophylactic PPI therapy Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: Prophylactic PPI therapy Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding: Prophylactic PPI therapy (...) Leontiadis G I, Sreedharan A, Dorward S, Barton P, Delaney B, Howden C W, Orhewere M, Gisbert J, Sharma V K, Rostom A, Moayyedi P, Forman D CRD summary This review concluded that H 2 RAs effectively reduced the risk of gastric and/or duodenal ulcers resulting from NSAID use, but standard-dose H 2 RAs were inferior to proton pump inhibitors and misoprostol. The authors' conclusions appeared to reflect the evidence presented, but the reliability of the conclusions is unclear due to limitations of the data

2007 DARE.

138. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials

Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

139. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease

Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

140. The clinical- and cost-effectiveness of proton pump inhibitors in acute upper gastro-intestinal bleeding

The clinical- and cost-effectiveness of proton pump inhibitors in acute upper gastro-intestinal bleeding Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, sharma VK, Rostom (...) A, Moayyedi P, Forman D Record Status This is a bibliographic record of an ongoing health technology assessment being undertaken by a member of INAHTA. Links to the published report and any other relevant documentation will be added when available. Citation Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, sharma VK, Rostom A, Moayyedi P, Forman D. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper

2007 Health Technology Assessment (HTA) Database.